-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KzsYRV2gEsdjpyhmrZu8vEl14XyvsDn8tIe/u1bBHdMq9u4A7KxOtNtzTviUN2bq iMZQsptWUUZDUuRImZ+8lQ== 0001144204-03-002908.txt : 20030529 0001144204-03-002908.hdr.sgml : 20030529 20030529170347 ACCESSION NUMBER: 0001144204-03-002908 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20030529 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: KERYX BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0001114220 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 134087132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-78786 FILM NUMBER: 03723968 BUSINESS ADDRESS: STREET 1: 216 JAFFA ROAD STREET 2: SHAAREI HAIR JERUSALEM CITY: ISRAEL 94383 BUSINESS PHONE: 9722534997 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ROSENWALD LINDSAY A MD CENTRAL INDEX KEY: 0000941841 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 375 PARK AVE STREET 2: SUITE 1501 CITY: NEW YORK STATE: NY ZIP: 10152 BUSINESS PHONE: 2128324366 MAIL ADDRESS: STREET 1: 375 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10152 FORMER COMPANY: FORMER CONFORMED NAME: ROSENWALD LINDSAY MD DATE OF NAME CHANGE: 19950316 SC 13D 1 doc1.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) KERYX BIOPHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $.001 PER SHARE (Title of Class of Securities) 492515101 (CUSIP Number) Lindsay A. Rosenwald, MD 787 Seventh Avenue, 48th Floor New York, NY 10019 (212) 554-4300 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 15, 2003 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ] Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Continued on following page(s) Page 1 of 5 - ------------------------------------ ------------------------------ CUSIP No. 492515101 SCHEDULE 13D - -------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Lindsay A. Rosenwald, M.D. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (See Instructions) OO (see Item 3 below) - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION United States - -------------------------------------------------------------------------------- NUMBER OF SHARES 7 SOLE VOTING POWER BENEFICIALLY OWNED BY 3,017,523 EACH REPORTING PERSON WITH -------------------------------------- 8 SHARED VOTING POWER 194,600 -------------------------------------- 9 SOLE DISPOSITIVE POWER 3,017,523 -------------------------------------- 10 SHARED DISPOSITIVE POWER 194,600 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,212,123 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES (See Instructions) - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 15.8% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (See Instructions) IN - -------------------------------------------------------------------------------- Item 1. Item 1. Security and Issuer. ------------------- (a) Common Stock, $.001 par value ("Shares") Page 2 of 5 Keryx Biopharmaceuticals, Inc. (the "Issuer") 750 Lexington Avenue New York, NY 10022 (212) 531-5965 Item 2. Identity and Background. ----------------------- Names of Persons Filing: (a) This statement is filed on behalf of Lindsay A. Rosenwald, M.D. ("Dr. Rosenwald" or the "Reporting Party"). (b) Dr. Rosenwald's business address is 787 Seventh Avenue, 48th Floor, New York, New York, 10019. (c) Dr. Rosenwald is an investment banker, venture capitalist and fund manager. (d) Dr. Rosenwald, has not, during the five years prior to the date hereof, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) Dr. Rosenwald has not been, during the five years prior to the date hereof, parties to a civil proceeding of a judicial or administrative body of competent jurisdiction, as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. (f) Dr. Rosenwald is a citizen of the United States. Item 3. Source and Amount of Funds or Other Consideration. ------------------------------------------------- The Reporting Parties sold Shares of the Issuer in a single transaction to the Rosenwald 2000 Family Trust, a trust established for the benefit of Dr. Rosenwald's minor children (the "Family Trust") at a price per share equal to $1.36. Dr. Rosenwald does not control the right to vote or dispose of the shares held by the Family Trust. Item 4. Purpose of Transaction. ---------------------- Except as indicated in this Schedule 13D, the Reporting Party currently has no plans or proposals that relate to or would result in any of the matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Item 5. Interest in Securities of the Issuer. ------------------------------------ (a) As of May 15, 2002, Dr. Rosenwald beneficially owned 3,209,623 Shares or 15.8% of the total amount of Shares outstanding assuming the exercise of all of the securities held by the following:
Percent Amount Owned ------- ---------------- Dr. Rosenwald 15.8% 2,714,428 Shares
Page 3 of 5
Percent Amount Owned ------- ---------------- 14,064 warrants to purchase Shares 10,000 director's options Paramount Capital Investments, LLC 1.5% 250,485 Shares and 50,110 warrants to purchase Shares Paramount Capital Asset Management, Inc. 0.9% 194,600 Shares
(b) Dr. Rosenwald is the Chairman and sole stockholder of Paramount Capital Asset Management, Inc. ("PCAM"), which is the manager of several investment funds that own shares of the Issuer and Paramount Capital Investment, LLC. Dr. Rosenwald and PCAM share the power to vote or to direct the vote, to dispose or to direct the disposition of those shares owned by such funds. (c) Other than as otherwise set forth herein the Reporting Parties have not engaged in any transactions in Shares during the past 60 days. (d) Not applicable (e) Not applicable. Item 6. Contracts, Arrangements, Understandings or Relationships with respect to Securities of the Issuer: ------------------------------------ Item 4 is herein incorporated by reference. In addition, Dr. Rosenwald serves as the Chairman of the Board of Directors of the Issuer. Item 7. Material to be Filed as Exhibits: -------------------------------- None. Page 4 of 5 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: May 15, 2003 New York, NY By: /s/ Lindsay A. Rosenwald, M.D. -------------------------- Lindsay A. Rosenwald, M.D. Page 5 of 5 -----END PRIVACY-ENHANCED MESSAGE-----